Kiniksa Pharmaceuticals reported strong third-quarter results, with ARCALYST revenue reaching $180.9 million, reflecting significant growth and a revised full-year sales guidance increase.

• ARCALYST revenue grew by approximately $69 million year-over-year and $24 million sequentially.
• Full-year net sales guidance raised to $670 million - $675 million, up from previous guidance of $625 million - $640 million.
• KPL-387 received FDA Orphan Drug Designation for recurrent pericarditis, enhancing future growth potential.
• New patient enrollments surged, with a total prescriber count exceeding 3,825, indicating strong market penetration and adoption.
• The average duration of ARCALYST therapy increased to approximately 32 months, reflecting patient satisfaction and treatment effectiveness.